High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors

The prognostic value of BRAF V600 mutation level on clinical outcomes in patients with BRAF V600-mutated metastatic melanoma treated with BRAF and MEK inhibitors remains uncertain. The association was retrospectively analysed between BRAF V600 mutation level (defined as the ratio of the quantificati...

Full description

Saved in:
Bibliographic Details
Main Authors: Ariane Fizazi, Chris Serrand, Alexandre Evrard, Blanche Bergeret, Pierre-Emmanuel Stoebner, Myriam Marque
Format: Article
Language:English
Published: Medical Journals Sweden 2024-11-01
Series:Acta Dermato-Venereologica
Subjects:
melanoma
BRAF V600
MAPKi
biomarker
Online Access:https://medicaljournalssweden.se/actadv/article/view/40913
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items